

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
13 June 2002 (13.06.2002)

PCT

(10) International Publication Number  
**WO 02/046237 A3**

(51) International Patent Classification<sup>7</sup>: **C07K 16/18**,  
A61P 25/28, A61K 39/395, C12N 15/13, 15/85, 5/10

(21) International Application Number: PCT/US01/46587

(22) International Filing Date: 6 December 2001 (06.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/251,892 6 December 2000 (06.12.2000) US

(71) Applicants (*for all designated States except US*): **NEURALAB LIMITED** [—/—]; 102 St. James Court, Flatts, Smiths, FL04 (BM). **WYETH** [US/US]; Five Giralda Farms, Madison, NJ 07940 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BASI, Guriq** [US/US]; 514 Rhoades Drive, Palo Alto, CA 94303 (US). **SALDANHA, Jose** [GB/GB]; 22A Lincoln Way, Enfield, Middlesex EN1 1TE (GB). **YEDNOCK, Ted** [US/US]; 184 Arroyo Road, Forest Knolls, CA 94933 (US).

(74) Agents: **MANDRAGOURAS, Amy, E.** et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:  
4 September 2003

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE

(57) Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/46587

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K16/18 A61P25/28 A61K39/395 C12N15/13 C12N15/85  
C12N5/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, SEQUENCE SEARCH, MEDLINE, BIOSIS, EPO-Internal, WPI Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BARD F ET AL: "Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease." NATURE MEDICINE. UNITED STATES AUG 2000, vol. 6, no. 8, August 2000 (2000-08), pages 916-919, XP002227088 ISSN: 1078-8956 abstract page 918; table 1	1-68, 71-143, 146-158
X	WO 00 23082 A (YEDA RESEARCH AND DEVELOPMENT CO. LTD., ISRAEL) 27 April 2000 (2000-04-27) figure 9 --- -/--	63,138

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

4 April 2003

Date of mailing of the international search report

17.04.2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2

NL - 2280 HV Rijswijk

Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,

Fax: (+31-70) 340-3016

Authorized officer

COVONE-VAN HEES, M

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/46587

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE WPI  Section Ch, Week 199534  Derwent Publications Ltd., London, GB;  Class B04, AN 1995-261292  XP002227089  &amp; JP 07 165799 A (ASAHI BREWERIES LTD),  27 June 1995 (1995-06-27)  abstract</p> <p>---</p>	65,140
X	<p>FRENKEL D ET AL: "HIGH AFFINITY BINDING  OF MONOCLONAL ANTIBODIES TO THE SEQUENTIAL  EPITOPE EFRH OF BETA-AMYLOID PEPTIDE IS  ESSENTIAL FOR MODULATION OF FIBRILLAR  AGGREGATION"  JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER  SCIENCE PUBLISHERS BV, XX,  vol. 95, 1999, pages 136-142, XP001001345  ISSN: 0165-5728  page 141, right-hand column, line 10-25  abstract</p> <p>---</p>	84-120, 122-137, 142,143, 146-154, 157,158
P,X	<p>WO 00 72880 A (SCHENK DALE B ;YEDNOCK TED  (US); BARD FREDERIQUE (US); NEURALAB LT)  7 December 2000 (2000-12-07)</p> <p>page 3, line 24-31  page 19, line 20-24  page 21, line 20 -page 22, line 34  examples 11,12</p> <p>---</p>	1-68, 71-83, 138-141, 149,155, 156
E	<p>WO 02 088306 A (LILLY CO ELI ;TSURUSHITA  NAOYA (US); VASQUEZ MAXIMILANO (US))  7 November 2002 (2002-11-07)</p> <p>page 2, line 5 -page 3, line 6  page 21, line 32 -page 22, line 23  claims</p> <p>---</p>	1-68, 71-83, 138-141, 149,155, 156
E	<p>WO 02 088307 A (LILLY CO ELI ;HINTON PAUL  ROBERT (US); VASQUEZ MAXIMILANO (US))  7 November 2002 (2002-11-07)</p> <p>page 2, line 17 -page 3, line 16  page 20, line 10-15  example 1</p> <p>---</p> <p>---  -/--</p>	84-137, 142,143, 146-154, 157,158

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/46587

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>KETTLEBOROUGH C A ET AL: "HUMANIZATION OF A MOUSE MONOCLONAL ANTIBODY BY CDR-GRAFTING: THE IMPORTANCE OF FRAMEWORK RESIDUES ON LOOP CONFORMATION" PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 4, no. 7, 1 October 1991 (1991-10-01), pages 773-783, XP002048549 ISSN: 0269-2139 the whole document</p> -----	<p>1-68, 71-143, 146-158</p>

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/46587

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 58-61,133-136 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 69,70,144,145  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-83,138-141,155,156 (complete) 149 (partially)

Humanized immunoglobulin (Ig) light chain and heavy chain comprising (i) variable region complementarity determining regions (CDRs) from 3D6 Ig light and heavy chain variable regions sequence set forth as seq ID. 2 and 4 respectively, and (ii) variable framework region from a human acceptor Ig light and heavy chain, provided that at least one framework residue is substituted with the corresponding amino acid residue from the mouse 3D6 light and heavy chain variable region sequence. Furthermore, the subject matter comprises the related products and methods: chimeric Ig comprising CDRs from 3D6 Ig or antigen binding fragment thereof, comprising a variable heavy and light chain (set forth as seq. ID 8, 12 and seq. ID 5,11 respectively), humanized antibody, method of preventing or treating an amyloidogenic disease and Alzheimer in patients, pharmaceutical compositions comprising said Ig, isolated polypeptide or fragments (as referred to in claims 63-66), a variant of said polypeptide, nucleic acid, vectors and host cells to encode and produce said Ig, method to produce said Ig. Method for identifying residues amenable to substitution in a humanized 3D6 variable framework region and use of the variable sequence to produce a three dimensional image of 3D6 Ig.

2. Claims: 84-137,142-148,150-154,157,  
158 (complete) 149 (partially)

Humanized immunoglobulin (Ig) light chain and heavy chain comprising (i) variable region complementarity determining regions (CDRs) from 10D5 Ig light and heavy chain variable regions sequence set forth as seq ID. 14 and 16 respectively, and (ii) variable framework region from a human acceptor Ig light and heavy chain, provided that at least one framework residue is substituted with the corresponding amino acid residue from the mouse 10D5 light and heavy chain variable region sequence. Furthermore, the subject matter comprises the related products and methods: chimeric Ig, humanized antibody, method of preventing or treating an amyloidogenic disease and Alzheimer in patients, pharmaceutical compositions comprising said Ig, isolated polypeptide, a variant of said polypeptide, nucleic acid, vectors and host cells to encode and produce said Ig, method to produce said Ig. Method for identifying residues amenable to substitution in a humanized 10D5 variable framework region and use of the variable sequence to produce a three dimensional image of 10D5 Ig.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 69,70,144,145

Present claims 69,70,144,145 relate to an extremely large number of possible products. In fact, the claims contain so many possible variants that a lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has not been carried out.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/46587

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0023082	A	27-04-2000	CA 2354862 A1 EP 1150688 A1 WO 0023082 A1	27-04-2000 07-11-2001 27-04-2000
JP 7165799	A	27-06-1995	NONE	
WO 0072880	A	07-12-2000	AU 5303100 A BG 106241 A BR 0011000 A CN 1359301 T CZ 20013824 A3 DE 10084643 T0 EE 200100626 A EP 1185298 A2 GB 2368794 A HU 0201250 A2 NO 20015773 A SK 16982001 A3 TR 200103447 T2 TR 200202231 T2 WO 0072880 A2	18-12-2000 30-08-2002 19-02-2002 17-07-2002 13-11-2002 11-07-2002 17-02-2003 13-03-2002 15-05-2002 28-08-2002 25-01-2002 06-11-2002 22-04-2002 21-11-2002 07-12-2000
WO 02088306	A	07-11-2002	WO 02088306 A2	07-11-2002
WO 02088307	A	07-11-2002	WO 02088307 A2	07-11-2002